WO2004006910A1 - Lipidoxidationsprodukte zur hemmung von entzündungen - Google Patents
Lipidoxidationsprodukte zur hemmung von entzündungen Download PDFInfo
- Publication number
- WO2004006910A1 WO2004006910A1 PCT/AT2003/000198 AT0300198W WO2004006910A1 WO 2004006910 A1 WO2004006910 A1 WO 2004006910A1 AT 0300198 W AT0300198 W AT 0300198W WO 2004006910 A1 WO2004006910 A1 WO 2004006910A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lps
- expression
- oxidation products
- oxpapc
- vitro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
Definitions
- Lipid oxidation products to inhibit inflammation Lipid oxidation products to inhibit inflammation.
- the invention relates to the use of lipid oxidation products to inhibit inflammation caused by bacterial infection.
- Inflammation mediators such as bacterial lipopolysaccharide (LPS), tumor necrosis factor (TNF) or rnterleukin-1 (IL-1) signal transduction pathways are switched on in endofuel cells, which translocate the nuclear factor kappa B (NFkB) transcription factor into the cell nucleus, which leads to the expression of inflammatory genes is turned on. This leads to the expression of cytokines and adhesion molecules and subsequently to the adhesion and transmigration of white blood cells to and through the endothelium.
- LPS bacterial lipopolysaccharide
- TNF tumor necrosis factor
- IL-1 rnterleukin-1
- Oxidized l-palmitoyl-2-arachidonyl-sn-glycerophosphorylcholine (OxPAPC)
- Oxidized low-density lipoprotein a cause of atherosclerosis, as well as in various inflammatory tissues and in atherosclerotic lesions, specifically stimulates endothelial cells to produce monocytes , an effect that plays an important role especially in chronic inflammatory diseases.
- oxPAPC stimulates the expression of tissue factor (TF) in endothelial cells.
- oxPAPC increases intracellular calcium levels. This leads to an activation of calcineurin and subsequently to the translocation of NFAT (nuclear factor of activated T-cells) into the cell nucleus.
- oxPAPC activates the expression of TF in endothelial cells by activating the following signaling pathways, regardless of NFDB: PKC-ERKl / 2-egr-l and
- Free arachidonic acid is converted from activated 12/15 lipoxygenase into specific lipoxygenase products, which are likely to act as ligands for PPARs and thus initiate a previously unknown mechanism that ultimately leads to the expression of adhesion molecules (not VCAM, ICAM, or E-selectin), effect specific monocyte adhesion.
- adhesion molecules not VCAM, ICAM, or E-selectin
- LPS Lipopolysaccharide
- LBP LPS-binding protein
- CD 14 LPS is its Present receptor (toll-like receptor 4, TLR4).
- This process expresses inflammatory genes by activating NFkB uuu ivi ur kinase signaling pathways.
- ROS reactive oxygen species
- lipid oxidation products formed in inflammatory processes could function as a negative feedback mechanism to inhibit so-called innate immune responses.
- chemical structures responsible for the inhibition identified in this study can be used to develop new drugs for the treatment of sepsis.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003243806A AU2003243806A1 (en) | 2002-07-15 | 2003-07-15 | Lipid oxidation products for inhibiting inflammation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ATA1061/2002 | 2002-07-15 | ||
AT10612002 | 2002-07-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004006910A1 true WO2004006910A1 (de) | 2004-01-22 |
Family
ID=30004252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AT2003/000198 WO2004006910A1 (de) | 2002-07-15 | 2003-07-15 | Lipidoxidationsprodukte zur hemmung von entzündungen |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2003243806A1 (de) |
WO (1) | WO2004006910A1 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006059082A1 (en) * | 2004-11-30 | 2006-06-08 | Trigen Limited | Oxidised lipids as reversal agents for boronic acid drugs |
WO2008154008A1 (en) * | 2007-06-11 | 2008-12-18 | The Scripps Research Institute | Methods and compositions for inhibiting toll-like receptor mediated immune responses |
WO2013107839A2 (en) * | 2012-01-20 | 2013-07-25 | Technische Universität Graz | Phospholipid compounds for use in skin cancer treatment |
WO2016115097A2 (en) | 2015-01-12 | 2016-07-21 | Children's Medical Center Corporation | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002041827A2 (en) * | 2000-11-24 | 2002-05-30 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
-
2003
- 2003-07-15 AU AU2003243806A patent/AU2003243806A1/en not_active Abandoned
- 2003-07-15 WO PCT/AT2003/000198 patent/WO2004006910A1/de not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002041827A2 (en) * | 2000-11-24 | 2002-05-30 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
Non-Patent Citations (5)
Title |
---|
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2003 (2003-03-01), BOCHKOV VALERY N ET AL: "Oxidized phospholipids inhibit endotoxin-induced inflammation by interfering with binding of LPS to LBP/CD14.", XP002258038, Database accession no. PREV200300347202 * |
ELIGINI SONIA ET AL: "Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-kappaB/IkappaB- and ERK2-dependent mechanisms", CARDIOVASCULAR RESEARCH, vol. 55, no. 2, 1 August 2002 (2002-08-01), pages 406 - 415, XP002258036, ISSN: 0008-6363 * |
FASEB JOURNAL, vol. 17, no. 4-5, March 2003 (2003-03-01), FASEB Meeting on Experimental Biology: Translating the Genome;San Diego, CA, USA; April 11-15, 2003, pages Abstract No. 762.5, ISSN: 0892-6638 (ISSN print) * |
ISUMI YOSHITAKA ET AL: "Regulation of adrenomedullin production in rat endothelial cells", ENDOCRINOLOGY, vol. 139, no. 3, March 1998 (1998-03-01), pages 838 - 846, XP002258037, ISSN: 0013-7227 * |
LEITINGER N ET AL: "STRUCTURALLY SIMILAR OXIDIZED PHOSPHOLIPIDS DIFFERENTIALLY REGULATE ENDOTHELIAL BINDING OF MONOCYTES AND NEUTROPHILS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 96, no. 21, 12 October 1999 (1999-10-12), pages 12010 - 12015, XP002951991, ISSN: 0027-8424 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006059082A1 (en) * | 2004-11-30 | 2006-06-08 | Trigen Limited | Oxidised lipids as reversal agents for boronic acid drugs |
WO2008154008A1 (en) * | 2007-06-11 | 2008-12-18 | The Scripps Research Institute | Methods and compositions for inhibiting toll-like receptor mediated immune responses |
WO2013107839A2 (en) * | 2012-01-20 | 2013-07-25 | Technische Universität Graz | Phospholipid compounds for use in skin cancer treatment |
WO2013107839A3 (en) * | 2012-01-20 | 2013-11-14 | Technische Universität Graz | Phospholipid compounds for use in skin cancer treatment |
WO2016115097A2 (en) | 2015-01-12 | 2016-07-21 | Children's Medical Center Corporation | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
WO2016115097A3 (en) * | 2015-01-12 | 2016-09-09 | Children's Medical Center Corporation | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
US11351250B2 (en) | 2015-01-12 | 2022-06-07 | Children's Medical Center Corporation | Pro-inflammatory and anti-cancer functions of toll-like receptor 4 antagonists |
US11400153B2 (en) | 2015-01-12 | 2022-08-02 | Children's Medical Center Corporation | Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists |
Also Published As
Publication number | Publication date |
---|---|
AU2003243806A1 (en) | 2004-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Marchetti et al. | NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis | |
Chiang et al. | Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors | |
Serhan et al. | Lipid mediators in the resolution of inflammation | |
Norling et al. | Proresolving and cartilage-protective actions of resolvin D1 in inflammatory arthritis | |
Gallo et al. | Inflammation and its resolution and the musculoskeletal system | |
Serhan et al. | Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain | |
Yedgar et al. | Control of phospholipase A2 activities for the treatment of inflammatory conditions | |
RU2444356C2 (ru) | Полиненасыщенные жирные кислоты для лечения деменции и состояний, связанных с преддеменцией | |
Freese et al. | Comparison of the effects of two diets rich in monounsaturated fatty acids differing in their linoleic/α-linolenic acid ratio on platelet aggregation | |
Orefice et al. | Oral palmitoylethanolamide treatment is associated with reduced cutaneous adverse effects of interferon-β1a and circulating proinflammatory cytokines in relapsing–remitting multiple sclerosis | |
Fan et al. | Characterization and inducing melanoma cell apoptosis activity of mannosylerythritol lipids-A produced from Pseudozyma aphidis | |
DE69833971T2 (de) | Verfahren zur behandlung der alzheimerschen krankheit | |
Xu et al. | Resolvin D1 attenuates imiquimod-induced mice psoriasiform dermatitis through MAPKs and NF-κB pathways | |
Nadeem et al. | Bruton’s tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice | |
Liu et al. | Lidocaine protects against renal and hepatic dysfunction in septic rats via downregulation of Toll‑like receptor 4 | |
Hossain et al. | Biological functions of plasmalogens | |
Chen et al. | Potential protective effect of Trans-10-hydroxy-2-decenoic acid on the inflammation induced by Lipoteichoic acid | |
Shang et al. | Inflammation resolution and specialized pro-resolving lipid mediators in CNS diseases | |
Zou et al. | The synergistic anti-inflammatory activities of agaro-oligosaccharides with different degrees of polymerization | |
Olafsdottir et al. | A heteroglycan from the cyanobacterium Nostoc commune modulates LPS-induced inflammatory cytokine secretion by THP-1 monocytes through phosphorylation of ERK1/2 and Akt | |
Mohaibes et al. | The hydroxylated form of docosahexaenoic acid (DHA-H) modifies the brain lipid composition in a model of Alzheimer's disease, improving behavioral motor function and survival | |
Qian et al. | The antioxidant and anti-inflammatory effects of abalone intestine digest, Haliotis discus hannai in RAW 264.7 macrophages | |
CZ161898A3 (cs) | Hydrolýzně optimalizované lipidové emulze a jejich použití | |
WO1998047502A1 (de) | IBUPROFENTHIOESTER ALS HEMMER DER Nf-λB ABHÄNGIGEN BILDUNG VON MEDIATOREN VON ENTZÜNDUNG UND SCHMERZ | |
Fattori et al. | Neuroimmune communication in infection and pain: friends or foes? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 91722003 Country of ref document: AT |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |